Eli Lilly ROE 2006-2018 | LLY

Current and historical return on equity (ROE) values for Eli Lilly (LLY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Eli Lilly ROE for the three months ending June 30, 2018 was 39.84%.
Eli Lilly ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-06-30 $-0.14B $11.62B -1.09%
2018-03-31 $1.12B $14.59B 8.12%
2017-12-31 $-0.20B $11.67B -1.49%
2017-09-30 $2.23B $14.96B 15.53%
2017-06-30 $2.45B $14.17B 16.88%
2017-03-31 $2.19B $14.10B 14.96%
2016-12-31 $2.74B $14.08B 18.44%
2016-09-30 $2.44B $15.62B 16.32%
2016-06-30 $2.47B $14.66B 16.57%
2016-03-31 $2.32B $15.03B 15.57%
2015-12-31 $2.41B $14.59B 16.20%
2015-09-30 $2.36B $15.24B 15.66%
2015-06-30 $2.06B $14.71B 13.14%
2015-03-31 $2.19B $14.95B 13.29%
2014-12-31 $2.39B $15.39B 13.78%
2014-09-30 $2.69B $17.68B 15.01%
2014-06-30 $3.39B $18.00B 19.14%
2014-03-31 $3.86B $18.35B 22.69%
2013-12-31 $4.68B $17.64B 28.95%
2013-09-30 $4.78B $16.90B 30.93%
2013-06-30 $4.91B $15.24B 32.17%
2013-03-31 $4.63B $14.96B 30.79%
2012-12-31 $4.09B $14.77B 27.28%
2012-09-30 $4.12B $16.06B 28.06%
2012-06-30 $4.03B $14.31B 27.92%
2012-03-31 $4.30B $14.82B 29.83%
2011-12-31 $4.35B $13.54B 30.61%
2011-09-30 $4.66B $15.06B 33.47%
2011-06-30 $4.73B $14.28B 35.65%
2011-03-31 $4.88B $13.93B 39.83%
2010-12-31 $5.07B $12.41B 44.56%
2010-09-30 $4.82B $12.41B 45.18%
2010-06-30 $4.45B $10.24B 44.40%
2010-03-31 $4.26B $10.46B 44.36%
2009-12-31 $4.33B $9.53B 48.48%
2009-09-30 $-0.22B $9.91B -2.61%
2009-06-30 $-1.62B $8.56B -17.66%
2009-03-31 $-1.82B $7.73B -16.98%
2008-12-31 $-2.07B $6.74B -16.53%
2008-09-30 $2.41B $13.74B 16.95%
2008-06-30 $3.80B $14.74B 27.12%
2008-03-31 $3.51B $14.91B 26.51%
2007-12-31 $2.95B $13.50B 23.84%
2007-09-30 $2.23B $12.95B 18.98%
2007-06-30 $2.18B $11.56B 18.49%
2007-03-31 $2.34B $11.53B 19.68%
2006-12-31 $2.66B $10.98B 22.35%
2006-09-30 $3.23B $13.06B 27.23%
2006-06-30 $3.15B $11.93B 27.53%
2006-03-31 $2.08B $11.69B 18.83%
2005-12-31 $1.98B $10.79B 17.98%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $120.201B $22.871B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $373.058B 17.49
Pfizer (PFE) United States $264.902B 15.51
Novartis AG (NVS) Switzerland $202.059B 17.26
Merck (MRK) United States $195.069B 17.23
AbbVie (ABBV) United States $133.211B 13.01
Sanofi (SNY) France $111.785B 14.15
Novo Nordisk (NVO) Denmark $105.487B 16.86
GlaxoSmithKline (GSK) United Kingdom $101.355B 13.53
AstraZeneca (AZN) United Kingdom $99.315B 10.92
Bristol-Myers Squibb (BMY) United States $88.755B 16.07